Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib Standard vs High Dose in High Risk CML
NCT00514488Phase 3Completed
- Sponsor
- Alma Mater Studiorum – Università di Bologna
- Start
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of imatinib in chronic myeloid leukemia (CML), sponsored by Alma Mater Studiorum – Università di Bologna. Started Jun 2004; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00514488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00514488.